PharmaShots | Incisive News in 3 Shots

Subscribe Now

Neurocrine

Neurocrine Presents P-III Studies (KINECT 3 & 4) Results of Ingrezza (valbenazine) for Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder at SIRS 2023

Neurocrine Presents P-III Studies (KINECT 3 & 4) Results of Ingrezza (valbenazine) for Tardive Dyskinesia and Schizophrenia or Sch...

May 17, 2023

Neurocrine and Voyager Collaborated to Develop Multiple Gene Therapies for the Treatment of Neurological Diseases

Neurocrine and Voyager Collaborated to Develop Multiple Gene Therapies for the Treatment of Neurological Diseases

January 10, 2023

Disease of the Month: Cerebral Palsy

Disease of the Month: Cerebral Palsy

October 18, 2022

Neurocrine Reports Results of Valbenazine in P-III (KINECT-HD) Study for the Treatment of Chorea Associated with Huntington Disease

Neurocrine Reports Results of Valbenazine in P-III (KINECT-HD) Study for the Treatment of Chorea Associated with Huntington Diseas...

December 8, 2021

PharmaShots Interview: Neurocrine's Dr. Eiry Roberts Shares Insight on Ongentys (opicapone)

PharmaShots Interview: Neurocrine's Dr. Eiry Roberts Shares Insight on Ongentys (opicapone)

November 16, 2020

PharmaShots Weekly Snapshot (Jun 15-19, 2020)

PharmaShots Weekly Snapshot (Jun 15-19, 2020)

June 22, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us